{
  "docId": "019de074-2763-7087-8fbd-df19b6e58266",
  "docSlug": "1ca51573de190fbfcf19415b61000ddd",
  "documentTitle": "AstraZeneca | Investor Conference Presentation Deck | 18 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 18,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Includes clinical trial data visualization and deal structure details.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2763-7087-8fbd-df19b6e58266/10",
  "deckHref": "/decks/019de074-2763-7087-8fbd-df19b6e58266",
  "deckJsonHref": "/decks/019de074-2763-7087-8fbd-df19b6e58266.json",
  "deckAnchorHref": "/decks/019de074-2763-7087-8fbd-df19b6e58266#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.14,
        "y": 0.55
      },
      "kind": "chart",
      "text": "Change in Systolic Blood Pressure over Time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d4bdc13-3695-45a8-863c-de6fcd9a80b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.5,
        "y": 0.22
      },
      "kind": "list",
      "text": "Hypertension: high-risk factor for stroke, CAD, heart attack and CKD; current treatment options limited. Baxdrostat is a potential leading next-generation ASI. Strong strategic fit to build leading cardiorenal portfolio.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "210fb97f-c99a-457a-945d-ca3ecf548493",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.42,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "Baxdrostat (CIN-107) – a highly selective, aldosterone synthase inhibitor (ASI). Baxdrostat is highly selective for aldosterone synthase and spares the cortisol pathway. BrighTN Phase II trial: Baxdrostat significantly reduced systolic BP.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a24d6eb-1010-4c49-b5e9-e0c670e5810a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "CCB = calcium channel blockers; BBs = beta blockers; ACE = angiotensin-converting enzyme; AE = adverse events; ARBs = angiotensin receptor blockers; ASI = aldosterone synthase inhibitors; MRAs = mineralocorticoid receptor antagonists; CAD = coronary arterial disease; CKD = chronic kidney disease; BP = blood pressure; trHTN = treatment-resistant hypertension.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc29dafb-4474-46da-842f-04534195cdf9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.5,
        "y": 0.58
      },
      "kind": "table",
      "text": "Deal terms: $26 per share in cash at deal closing ($1.3bn); AstraZeneca will acquire CinCor’s cash and marketable securities (~$0.5bn); A non-tradable contingent value right of $10 per share.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ba2b959-3d9b-4b58-9de6-9f6e4f4eb887",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.7,
        "x": 0.03,
        "y": 0.12
      },
      "kind": "title",
      "text": "A potential best-in-class ASI for treatment resistant hypertension",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c223ebe-184c-4d3e-8fee-82f132ec2a39",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Baxdrostat: addresses a large unmet need in cardiorenal disease",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f725cbd8-28d3-4976-8222-3782ceb0b47f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "148e3c75-ec2b-4cf6-8ba9-fc0b7645c2a8",
      "evidence": "type: executive_summary",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 9,
      "beatId": "d24e6f2d-ed7f-45f3-8426-4526ac01fda7",
      "arcName": "The Golden Circle",
      "arcSlug": "golden-circle",
      "beatName": "Thesis Headline",
      "beatSlug": null,
      "evidence": "A specific strategic action (acquisition) is highlighted to strengthen the pipeline.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    },
    {
      "to": 11,
      "from": 3,
      "beatId": "577d5e60-d812-43a3-83a5-243b94cfd455",
      "arcName": "The Golden Circle",
      "arcSlug": "golden-circle",
      "beatName": "Executive Summary",
      "beatSlug": null,
      "evidence": "Summarizing the company's position and strategy for growth.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "88983257-4d74-4000-ae54-8166a2051abc",
      "evidence": "The loop is visible in how the presentation starts with the company's mission and weaves through its growth strategy.",
      "position": 0,
      "objective": "To explain why AstraZeneca is positioned for growth and how it plans to achieve it",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.8,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    },
    {
      "to": 10,
      "from": 9,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "f577db34-3711-4966-ab1d-a155e7015552",
      "evidence": "The presentation highlights the strategic rationale for the acquisition at this time.",
      "position": 1,
      "objective": "To justify the timing of the acquisition of CinCor Pharma",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.7,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}